← Gansu Longshenrongfa Pharmaceutical Industry overview

Gansu Longshenrongfa Pharmaceutical Industry vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534.CS)

Q3 2026
▲2▼2

Policy Boost Fades as Profit Slump and Drug Setback Weigh

  • TCM policy tailwind The State Council approved the 15th Five-Year Plan for Traditional Chinese Medicine, a sector-wide boost that sent Longshen Rongfa up 20% on July 13 and again on July 20. This policy support improves the outlook for TCM companies, but the initial price spike may already reflect much of the news.

    This is the main positive force behind the stock's early-period surge.

  • Interim profit drops 40.67% Longshen Rongfa's 2026 interim net profit fell 40.67% year on year to 13.71 million yuan, with revenue down 30.96%. This weak financial performance is a major negative for the stock, as it shows the company's core business is struggling despite policy support.

    This is the most important company-specific negative news that directly impacts valuation.

  • Macao registration for key product Longshen Rongfa's flagship Yuanhu Zhitong Dripping Pills received a Macao registration certificate, allowing sales in Macao and expanding overseas business. While the company says it won't significantly impact near-term performance, it enhances brand and market competitiveness, a modest positive.

    This is a new positive development that could support long-term growth.

  • Drug application not approved Longshen Rongfa's controlling subsidiary's marketing application for brexpiprazole oral dissolving film was not approved. This regulatory setback removes a potential new revenue source and adds uncertainty to the company's product pipeline, weighing on sentiment.

    This is a new negative event that directly affects the company's future prospects.

August 2026
▲2▼2

Policy Boost Fades as Profit Slump and Drug Setback Weigh

  • TCM policy tailwind The State Council approved the 15th Five-Year Plan for Traditional Chinese Medicine, a sector-wide boost that sent Longshen Rongfa up 20% on July 13 and again on July 20. This policy support improves the outlook for TCM companies, but the initial price spike may already reflect much of the news.

    This is the main positive force behind the stock's early-period surge.

  • Interim profit drops 40.67% Longshen Rongfa's 2026 interim net profit fell 40.67% year on year to 13.71 million yuan, with revenue down 30.96%. This weak financial performance is a major negative for the stock, as it shows the company's core business is struggling despite policy support.

    This is the most important company-specific negative news that directly impacts valuation.

  • Macao registration for key product Longshen Rongfa's flagship Yuanhu Zhitong Dripping Pills received a Macao registration certificate, allowing sales in Macao and expanding overseas business. While the company says it won't significantly impact near-term performance, it enhances brand and market competitiveness, a modest positive.

    This is a new positive development that could support long-term growth.

  • Drug application not approved Longshen Rongfa's controlling subsidiary's marketing application for brexpiprazole oral dissolving film was not approved. This regulatory setback removes a potential new revenue source and adds uncertainty to the company's product pipeline, weighing on sentiment.

    This is a new negative event that directly affects the company's future prospects.

Latest
▲2▼2

Policy Boost Fades as Profit Slump and Drug Setback Weigh

  • TCM policy tailwind The State Council approved the 15th Five-Year Plan for Traditional Chinese Medicine, a sector-wide boost that sent Longshen Rongfa up 20% on July 13 and again on July 20. This policy support improves the outlook for TCM companies, but the initial price spike may already reflect much of the news.

    This is the main positive force behind the stock's early-period surge.

  • Interim profit drops 40.67% Longshen Rongfa's 2026 interim net profit fell 40.67% year on year to 13.71 million yuan, with revenue down 30.96%. This weak financial performance is a major negative for the stock, as it shows the company's core business is struggling despite policy support.

    This is the most important company-specific negative news that directly impacts valuation.

  • Macao registration for key product Longshen Rongfa's flagship Yuanhu Zhitong Dripping Pills received a Macao registration certificate, allowing sales in Macao and expanding overseas business. While the company says it won't significantly impact near-term performance, it enhances brand and market competitiveness, a modest positive.

    This is a new positive development that could support long-term growth.

  • Drug application not approved Longshen Rongfa's controlling subsidiary's marketing application for brexpiprazole oral dissolving film was not approved. This regulatory setback removes a potential new revenue source and adds uncertainty to the company's product pipeline, weighing on sentiment.

    This is a new negative event that directly affects the company's future prospects.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.